コンテンツへスキップ
Merck

In vitro susceptibilities of Mycoplasma putrefaciens field isolates.

Antimicrobial agents and chemotherapy (2007-07-20)
N T Antunes, M M Tavío, P Mercier, R D Ayling, W Al-Momani, P Assunção, R S Rosales, J B Poveda
要旨

MICs were determined for 15 antimicrobial agents against 37 Mycoplasma putrefaciens isolates. The most effective antimicrobial drug classes were the fluoroquinolones, the tetracyclines, the lincosamide lincomycin, and the macrolides. The susceptibility profile of the isolates correlated with the geographic origin. This is the first report of decreased susceptibility to the macrolides, lincomycin, and the tetracyclines in M. putrefaciens strains.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
エリスロマイシン, BioReagent, suitable for cell culture
Sigma-Aldrich
シプロフロキサシン, ≥98% (HPLC)
Sigma-Aldrich
ナリジクス酸, ≥98%
Sigma-Aldrich
エンロフロキサシン, ≥99.0%
Supelco
ノルフロキサシン, analytical standard, ≥98% (TLC)
Sigma-Aldrich
エリスロマイシン, potency: ≥850 μg per mg
Sigma-Aldrich
エリスロマイシン, meets USP testing specifications
Supelco
エンロフロキサシン, VETRANAL®, analytical standard
Supelco
シプロフロキサシン, VETRANAL®, analytical standard
Supelco
ノルフロキサシン, VETRANAL®, analytical standard
Sigma-Aldrich
エリスロマイシン, tested according to Ph. Eur.